

**REMARKS**

In the action, the Examiner required election between the following inventions.

Group I, claims 45-55, directed to a method for long term treatment of conditions of reduced protein tolerance; and, Group II, claims 56-62, directed to a composition containing the general formula represented in the claim.

Additionally, if Group I is elected, applicants are required to elect a species of one allele pair listed in claim 44, or if Group II is elected, one compound recited in claim 56.

Applicants provisionally elect Group I, claims 44-55, and the R261X+A300S mutation listed in claim 44 for examination on the merits. Claims 44-55 read on the elected invention.

**Support for the Amendment to the Claims**

Claim 44 has been amended to correct a typographical error. The mutation R261X +A300R should have correctly been identified as R261X+A300S. Support for the amendment is found in Table 1, pages 46-47 of the English specification submitted July 20, 2005, which lists the R261X+A300S mutation and not a R261X+A300R mutation. The amendment includes no new matter.

Applicant submits that the claims are in condition for allowance and request notification of the same.

Dated: February 2, 2009

Respectfully submitted,

By /Katherine L. Neville/

Katherine L. Neville

Registration No.: 53,379

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant